25 min listen
Early Market Access and Pricing with Pete Bak, Christian Thieniel and Brendan Wang
Early Market Access and Pricing with Pete Bak, Christian Thieniel and Brendan Wang
ratings:
Length:
30 minutes
Released:
Jul 6, 2022
Format:
Podcast episode
Description
This is the first episode in our podcast series of Q&As on biopharma and medtech development—directly from active developers. Our podcast listeners, including Back Bay clients, have submitted timely and relevant questions about life science development and the daily challenges they face.Christian Thieniel and Brendan Wang, two senior members of the Back Bay Life Science Advisors team with a tremendous amount of experience in the life sciences, especially as it relates to scientific, clinical and commercial issues, offer guidance on issues related to pricing and early market access.Topics include:
For early-stage clients, when is the right time to think about pricing and access, and why it is important to identify market access hurdles early
For later stage clients, how to get more granular on pricing and market access insights (narrowing the price range, broadening the payer sample, etc.)
Which real-life and project examples lend clarity here, including an example from Back Bay’s past work in the anti-infectives space. How can upfront P&MA research lead to more confidence and varied project positioning in partnering discussions?
Would you like us to include your life sciences development question in an upcoming episode? Please submit it here.Make sure to subscribe to our podcast on your favorite podcast platforms and follow Back Bay Life Science Advisors on LinkedIn.Thank you for joining us.
For early-stage clients, when is the right time to think about pricing and access, and why it is important to identify market access hurdles early
For later stage clients, how to get more granular on pricing and market access insights (narrowing the price range, broadening the payer sample, etc.)
Which real-life and project examples lend clarity here, including an example from Back Bay’s past work in the anti-infectives space. How can upfront P&MA research lead to more confidence and varied project positioning in partnering discussions?
Would you like us to include your life sciences development question in an upcoming episode? Please submit it here.Make sure to subscribe to our podcast on your favorite podcast platforms and follow Back Bay Life Science Advisors on LinkedIn.Thank you for joining us.
Released:
Jul 6, 2022
Format:
Podcast episode
Titles in the series (27)
Life Science SPACs: A Forward Look at this Evolving Asset Class: In this week’s episode Jonathan Gertler, Back Bay’s CEO and Managing Partner, is joined by Gregory Benning and Vasilios Kofitsas of Back Bay’s investment banking team to talk about the market of Special Purpose Acquisition Companies (SPACs). by Back Bay Life Science Report